Clinical trial • Phase I • Immunology
GSK4527363 for Systemic lupus erythematosus | Connective tissue disease-associated interstitial lung disease
Phase I trial of GSK4527363 for Systemic lupus erythematosus | Connective tissue disease-associated interstitial lung disease. 124 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Systemic lupus erythematosus | Connective tissue disease-associated interstitial lung disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 24-03-2025
- First CTIS Authorization Date
- 18-07-2025
Trial design
Phase I trial across 11 sites in Spain, Poland.
- Target Sample Size
- 124
Recruitment
- Planned Sample Size
- 124
- Recruitment Window Months
- 22
Geography
- Total Number Of Sites
- 11
- Total Number Of Participants
- 15
Spain
- Earliest CTIS Part Ii Submission Date
- 26-06-2025
- Latest Decision Or Authorization Date
- 16-03-2026
- Processing Time Days
- 263
- Number Of Sites
- 5
- Number Of Participants
- 7
Sites
- Site Name
- Hospital Universitario De Navarra
- Department Name
- Internal medicine
- Contact Person Name
- Patricia Fanlo Mateo
- Contact Person Email
- patricia.fanlo.mateo@navarra.es
- Site Name
- Hospital Universitario Rio Hortega
- Department Name
- Internal medicine
- Contact Person Name
- Julia Barbado Ajo
- Contact Person Email
- jbarbadoa@saludcastillayleon.es
- Site Name
- Hospital Universitario Basurto
- Department Name
- Rheumatology Dept
- Contact Person Name
- Maria Esther Ruiz Lucea
- Contact Person Email
- MARIAESTHER.RUIZLUCEA@osakidetza.eus
- Site Name
- Parc Tauli Hospital Universitari
- Department Name
- Rheumatology Dept
- Contact Person Name
- Joan Calvet Fontova
- Contact Person Email
- calvet.parctauli@gmail.com
- Site Name
- Hospital Germans Trias I Pujol
- Department Name
- Rheumatology Dept
- Contact Person Name
- Ivette Casafont Solé
- Contact Person Email
- icasafont.germanstrias@gencat.cat
Poland
- Earliest CTIS Part Ii Submission Date
- 13-06-2025
- Latest Decision Or Authorization Date
- 13-03-2026
- Processing Time Days
- 273
- Number Of Sites
- 6
- Number Of Participants
- 8
Sites
- Site Name
- Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
- Department Name
- Ośrodek Wczesnych Faz
- Contact Person Name
- Piotr Wiland
- Contact Person Email
- rnc@umw.edu.pl
- Site Name
- Uniwersytecki Szpital Kliniczny W Bialymstoku
- Department Name
- Klinika Reumatologii i Chorób Wewnętrznych
- Contact Person Name
- Otylia Kowal-Bielecka
- Contact Person Email
- reum@umb.edu.pl
- Site Name
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
- Department Name
- Oddział Kliniczny Reumatologii, Immunologii i Chorób Wewnętrznych
- Contact Person Name
- Mariusz Korkosz
- Contact Person Email
- mariusz.korkosz@uj.edu.pl
- Site Name
- Uniwersytecki Szpital Kliniczny W Poznaniu
- Department Name
- Uniwersytecki Ośrodek Wczesnych Faz
- Contact Person Name
- Włodzimierz Samborski
- Contact Person Email
- ucwbk@ump.edu.pl
- Site Name
- Klinika Reuma Park Sp. z o.o. S.K.
- Department Name
- Centrum Medyczne Reuma Park
- Contact Person Name
- Anna Zubrzycka-Sienkiewicz
- Contact Person Email
- info@reumatika.pl
- Site Name
- Medicover Integrated Clinical Services Sp. z o.o.
- Department Name
- Centrum Medyczne Bydgoszcz
- Contact Person Name
- Katarzyna Kolossa
- Contact Person Email
- katarzyna.kolossa@mics.medicover.com
Sponsor
Primary sponsor
- Full Name
- Glaxosmithkline Research & Development Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- GSK4527363
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis